Singapore markets closed

Eupraxia Pharmaceuticals Inc. (EPRX.TO)

Toronto - Toronto Real-time price. Currency in CAD
Add to watchlist
5.86+0.11 (+1.91%)
At close: 03:59PM EST
Currency in CAD

Valuation measures4

Market cap (intra-day) 159.76M
Enterprise value 141.97M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)9.37
Enterprise value/revenue N/A
Enterprise value/EBITDA -4.44

Trading information

Stock price history

Beta (5Y monthly) 1.43
52-week change 358.38%
S&P500 52-week change 315.38%
52-week high 39.10
52-week low 33.27
50-day moving average 36.05
200-day moving average 36.47

Share statistics

Avg vol (3-month) 323.89k
Avg vol (10-day) 310.01k
Shares outstanding 527.26M
Implied shares outstanding 627.26M
Float 821.26M
% held by insiders 111.17%
% held by institutions 118.21%
Shares short (29 Nov 2023) 4631.14k
Short ratio (29 Nov 2023) 453.44
Short % of float (29 Nov 2023) 44.38%
Short % of shares outstanding (29 Nov 2023) 42.32%
Shares short (prior month 30 Oct 2023) 4622.07k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Sept 2023


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-57.42%
Return on equity (ttm)-199.77%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -30.11M
Net income avi to common (ttm)-33.35M
Diluted EPS (ttm)-1.53
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)33.21M
Total cash per share (mrq)1.22
Total debt (mrq)15.41M
Total debt/equity (mrq)102.34%
Current ratio (mrq)1.75
Book value per share (mrq)0.62

Cash flow statement

Operating cash flow (ttm)-25.09M
Levered free cash flow (ttm)-15.41M